We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain (SUPPORT 2)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: March 25, 2009
Last Update Posted: January 28, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Cerimon Pharmaceuticals
March 24, 2009
March 25, 2009
January 28, 2010
February 2009
June 2009   (Final data collection date for primary outcome measure)
Change in average pain during daily activity at Day 3 [ Time Frame: Day 3 ]
Same as current
Complete list of historical versions of study NCT00869180 on ClinicalTrials.gov Archive Site
Change in average pain during daily activity at Day 7 [ Time Frame: Day 7 ]
Same as current
Not Provided
Not Provided
Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain
The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium topical patch in reducing acute pain due to mild to moderate ankle sprains when applied to the painful area.

This randomized, double-blind, placebo-controlled, parallel group study will be conducted in patients with mild or moderate ankle sprains.

Eligible patients will be randomized (in a 1:1 ratio) to receive double-blind treatment with either the diclofenac topical patch or a matching placebo patch to be applied once daily for 7 days. Patients will return to the clinic for assessments on Day 3 and Day 7; a follow-up assessment will be conducted on Day 14. Patients will complete an electronic diary in which assessments including pain intensity, pain relief and functional disability will be recorded twice daily. Ratings of the quality of sleep will be recorded in the diary each morning, and the use of study treatment and rescue medication will be recorded in the diary each day.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Acute Pain
  • Ankle Sprain
  • Drug: Diclofenac Sodium
    Topical diclofenac patch applied once daily to area of pain
  • Drug: Matching Placebo Patch
    Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
  • Experimental: Diclofenac Sodium Patch
    Intervention: Drug: Diclofenac Sodium
  • Placebo Comparator: Topical Placebo Patch
    Intervention: Drug: Matching Placebo Patch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2009
June 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female subjects 17 - 75 years of age
  • Sustained recent, painful unilateral mild to moderate ankle sprain
  • Meet baseline pain criterion

Exclusion Criteria:

  • Open wound or infection at site of injury
  • Evidence of severe injury or ankle fracture
  • Use of oral NSAIDs or opioids within 12 - 24 hours of injury
  • Presence or history of peptic ulcers or GI bleeding
  • A history of intolerance to NSAIDs, acetaminophen, adhesives
  • Positive pregnancy test
  • Positive drug screen
Sexes Eligible for Study: All
17 Years to 75 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Shaily J. Reichert, V.P. of Clinical Development, Cerimon Pharmaceuticals
Cerimon Pharmaceuticals
Not Provided
Cerimon Pharmaceuticals
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP